These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37309615)

  • 1. Topical N-phosphonacetyl-l-aspartate is a dual action candidate for treating non-melanoma skin cancer.
    Mahen KK; Markley L; Bogart J; Klatka H; Krishna V; Maytin EV; Stark GR; McDonald C
    Exp Dermatol; 2023 Sep; 32(9):1485-1497. PubMed ID: 37309615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Immunotherapy for Actinic Keratosis and Field Cancerization.
    Bernal Masferrer L; Gracia Cazaña T; Bernad Alonso I; Álvarez-Salafranca M; Almenara Blasco M; Gallego Rentero M; Juarranz de la Fuente Á; Gilaberte Y
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies.
    Gupta AK; Davey V; Mcphail H
    J Cutan Med Surg; 2005 Oct; 9(5):209-14. PubMed ID: 16502198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
    Tillman DK; Carroll MT
    Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies.
    Bahner JD; Bordeaux JS
    Clin Dermatol; 2013; 31(6):792-8. PubMed ID: 24160289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic pharmacology of topical imiquimod, 5-fluorouracil, and diclofenac for the dermatologic surgeon.
    Desai T; Chen CL; Desai A; Kirby W
    Dermatol Surg; 2012 Jan; 38(1):97-103. PubMed ID: 22092926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrimidine synthesis inhibition enhances cutaneous defenses against antibiotic resistant bacteria through activation of NOD2 signaling.
    Jatana S; Homer CR; Madajka M; Ponti AK; Kabi A; Papay F; McDonald C
    Sci Rep; 2018 Jun; 8(1):8708. PubMed ID: 29880914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
    Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
    Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod.
    Tutrone WD; Saini R; Caglar S; Weinberg JM; Crespo J
    Cutis; 2003 May; 71(5):365-70. PubMed ID: 12769403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical treatments for skin cancer.
    Cullen JK; Simmons JL; Parsons PG; Boyle GM
    Adv Drug Deliv Rev; 2020 Jan; 153():54-64. PubMed ID: 31705912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Field cancerization: from molecular basis to selective field-directed management of actinic keratosis.
    Philipp-Dormston WG
    Curr Probl Dermatol; 2015; 46():115-21. PubMed ID: 25561215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total body topical 5-fluorouracil for extensive non-melanoma skin cancer.
    van Ruth S; Jansman FG; Sanders CJ
    Pharm World Sci; 2006 Jun; 28(3):159-62. PubMed ID: 17004017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer.
    Lucena SR; Salazar N; Gracia-Cazaña T; Zamarrón A; González S; Juarranz Á; Gilaberte Y
    Int J Mol Sci; 2015 Oct; 16(10):25912-33. PubMed ID: 26516853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Non-Surgical and Cost-Effective Treatment Approach Employing Topical Imiquimod, 5-Fluorouracil, and Tretinoin for Primary Non-Melanoma Skin Cancers.
    Nahm WJ; Shen J; Zito PM; Gonzalez AM; Nagrani N; Moore K; Badiavas EV; Kirsner RS; Nichols AJ
    J Drugs Dermatol; 2021 Mar; 20(3):260-267. PubMed ID: 33683072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK; Inouye T; Goldin A; Stark GR
    Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.
    Neugebauer R; Su KA; Zhu Z; Sokil M; Chren MM; Friedman GD; Asgari MM
    J Am Acad Dermatol; 2019 Apr; 80(4):998-1005. PubMed ID: 30458208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of basal cell carcinoma: evolving approaches.
    Gaspari AA; Sauder DN
    Dermatol Surg; 2003 Oct; 29(10):1027-34. PubMed ID: 12974699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.
    Sinclair R; Baker C; Spelman L; Supranowicz M; MacMahon B
    Australas J Dermatol; 2021 May; 62(2):119-123. PubMed ID: 32840870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
    Cunningham TJ; Tabacchi M; Eliane JP; Tuchayi SM; Manivasagam S; Mirzaalian H; Turkoz A; Kopan R; Schaffer A; Saavedra AP; Wallendorf M; Cornelius LA; Demehri S
    J Clin Invest; 2017 Jan; 127(1):106-116. PubMed ID: 27869649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical therapy for actinic keratoses: current and evolving therapies.
    Weinberg JM
    Rev Recent Clin Trials; 2006 Jan; 1(1):53-60. PubMed ID: 18393780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.